Covid-19 vaccine inequity will have a lasting and profound impact on socio-economic recovery in low- and lower-middle income countries without urgent action to boost supply and assure equitable access for every country, including through dose sharing, according to new data released recently by the United Nations Development Programme (UNDP), the World Health Organization (WHO) and […]
Shimadzu, one of the world leaders in analytical instrumentation, has appointed Jürgen Semmler as the new managing director of its European organization from July 1, 2021. Previously, head of Shimadzu Deutschland, he succeeds Jürgen Kwass, who led Shimadzu Europa from 2003 to the present and is now retiring. Semmler and Kwass have both been affiliated […]
https://interhospi.com/wp-content/uploads/sites/3/2021/09/Shimadzu_Jürgen-Semmler.jpg984904panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-21 13:09:102021-09-21 13:09:10Jürgen Semmler appointed new managing director at Shimadzu Europe
Medovate has successfully secured additional CE Mark approvals for its SAFIRA (SAFer Injection for Regional Anaesthesia) technology to include an NRFit syringe and a Palm Operator
https://interhospi.com/wp-content/uploads/sites/3/2021/09/medovate_NRFit-scaled.jpg17062560panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-21 13:04:592021-09-21 13:11:36Medovate expands SAFIRA product range with further CE Mark approvals
Minaris Regenerative Medicine, a leading contract development and manufacturing organization for the cell and gene therapy industry, will be the commercial manufacturer in Europe for bluebird bio’s Skysona (elivaldogene autotemcel, formerly Lenti-D gene therapy), for the treatment of Early Cerebral Adrenoleukodystrophy (CALD).
https://interhospi.com/wp-content/uploads/sites/3/2021/09/Minaris-cleanroom.jpg13332000panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-21 13:01:532021-09-21 13:01:53Minaris to be commercial manufacturer in Europe for Skysona, bluebird bio’s gene therapy for CALD
Owen Mumford has been awarded a RoSPA (Royal Society for the Prevention of Accidents) gold health and safety award. The awarded is given to organisations that achieve exceptional control of risk with very low levels of error, harm and loss.
https://interhospi.com/wp-content/uploads/sites/3/2021/09/rospa.jpg891656panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-21 12:58:492021-09-21 12:58:49Owen Mumford receives RoSPA gold award for health and safety achievements
Siemens Healthineers has recently started offering its customers WeScan. WeScan is a new service that helps healthcare providers to perform magnetic resonance imaging (MRI) examinations if they lack qualified radiology staff. With the WeScan service, customers may seek access to a pool of skilled remote imaging technologists who help operate the MRI scanner using syngo […]
https://interhospi.com/wp-content/uploads/sites/3/2021/09/WeScan.png9011631panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-21 12:56:192021-09-21 12:56:19TeamViewer, Siemens Healthineers form partnership to enable new remote scanning service WeScan for diagnostic imaging
The US FDA has granted Fast Track designation to APB-102, Apic Bio’s lead gene therapy candidate designed to treat SOD1 amyotrophic lateral sclerosis (ALS). Apic said they plan to commence a Phase 1/2 clinical trial in early 2022.
https://interhospi.com/wp-content/uploads/sites/3/2021/09/apic_bio.jpg488842panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-21 12:51:352021-09-21 12:52:47Apic Bio receives FDA Fast Track Designation for APB-102 for treatment of patients with SOD1 ALS
Canon Medical Systems Corporation recently announced a major operational plan to strengthen its healthcare information technology (HIT) division which will see it broaden its capabilities and leverage Canon Medical’s global infrastructure to accelerate the delivery of a full range of Enterprise, AI, and collaborative imaging solutions. As part of the development, Vital Images, Inc. will […]
https://interhospi.com/wp-content/uploads/sites/3/2021/09/Canon-Medical-logo.jpg6761772panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-21 12:44:282021-09-21 12:48:43Canon Medical to reform global HIT division
CN Bio, a leading organ-on-a-chip company (OOC) that designs and manufactures singleand multi-organ microphysiological systems (MPS), has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and North-eastern University. Planned for commercial launch in 2023, the technology will be integrated into CN Bio’s PhysioMimix […]
https://interhospi.com/wp-content/uploads/sites/3/2021/09/shutterstock_1031178730-1-scaled.jpg17072560panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-21 12:29:482021-09-21 12:41:17CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University
Ashikaga Red Cross Hospital, Japan’s first green hospital
Leaders of the global healthcare community are invited to attend an important virtual event looking at developing innovative practices for a sustainable future.
It will bring together hospital executives from around the world to share their strategies and experiences in promoting sustainability in the healthcare sector.
Climate change – a major threat to public health
Hospital and healthcare professionals are at the forefront of the fight against climate change, which is at risk of becoming the biggest public health threat of our generation:
If the world’s healthcare sector were a country, it would be the fifth-largest emitter of carbon emissions on the planet.
Medical professionals have identified climate change from carbon emissions as the ‘biggest global health threat of the 21st century’. (The Lancet, Commission on Climate Change, 2009)
Between 2030 and 2050, climate change is expected to cause more than 250,000 additional deaths per year.
Dr. Satoru Komatsumoto, Emeritus Director of Ashikaga Red Cross Hospital, will share his insights into designing a resilient hospital.
The keynote speaker at the event will be Dr. Satoru Komatsumoto, Emeritus Director of Ashikaga Red Cross Hospital, which is Japan’s first green hospital Dr. Komatsumoto will share his insights into designing a resilient hospital.
He commented: “Sixteen years ago, I proposed that our hospital should be eco-conscious. I wanted to create a hospital that would be beautiful and that would organically integrate all the features to meet the challenges of the future… I wondered what kind of hospital would meet the needs of our time. I studied very hard to imagine a next generation hospital.”
The program also includes speakers from Europe and the USA who will share strategies to achieve net zero carbon emissions by 2030, sustainable food circuits and building a carbon-neutral hospital. There will also be dedicated time for small group discussions with the experts to explore innovative ideas.
You can register here for Green Hospitals: Sharing innovative practices for a sustainable future.
https://interhospi.com/wp-content/uploads/sites/3/2021/09/Komatsumoto_web.jpg790770panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-13 10:30:282021-09-13 10:30:28Join the Green Hospitals event to develop innovative practices for a sustainable future
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.